Search Results - "Voineskos, A.N."

Superior memory performance in healthy individuals with subclinical psychotic symptoms but without genetic load for schizophrenia by Gagnon, G, Kumar, S, Maltais, J.-R, Voineskos, A.N, Mulsant, B.H, Rajji, T.K

Get full text

The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia by Lett, T A, Chakavarty, M M, Felsky, D, Brandl, E J, Tiwari, A K, Gonçalves, V F, Rajji, T K, Daskalakis, Z J, Meltzer, H Y, Lieberman, J A, Lerch, J P, Mulsant, B H, Kennedy, J L, Voineskos, A N

“…We examined the influence of the genome-wide significant schizophrenia risk variant rs1625579 near the microRNA (miRNA)-137 ( MIR137 ) gene on well-established…”
Get full text

Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA by Suridjan, I., Rusjan, P.M., Voineskos, A.N., Selvanathan, T., Setiawan, E., Strafella, A.P., Wilson, A.A., Meyer, J.H., Houle, S., Mizrahi, R.

“…One of the cellular markers of neuroinflammation is increased microglia activation, characterized by overexpression of mitochondrial 18kDa Translocator Protein…”
Get full text

Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18 kDa (TSPO) radioligand, [18F]-FEPPA by SURIDJAN, I, RUSJAN, P. M, VOINESKOS, A. N, SELVANATHAN, T, SETIAWAN, E, STRAFELLA, A. P, WILSON, A. A, MEYER, J. H, HOULE, S, MIZRAHI, R

“…One of the cellular markers of neuroinflammation is increased microglia activation, characterized by overexpression of mitochondrial 18 kDa Translocator…”
Get full text

In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [[sup.18]F]-FEPPA by Suridjan, I, Pollock, B.G, Verhoeff, N.P.L.G, Voineskos, A.N, Chow, T, Rusjan, P.M, Lobaugh, N.J, Houle, S, Mulsant, B.H, Mizrahi, R

“…Our primary aim was to compare neuroinflammation in cognitively Intact control subjects and patients with Alzheimer's disease (AD) by using positron emission…”
Get full text

MIR137 polygenic risk for schizophrenia and ephrin-regulated pathway: Role in lateral ventricles and corpus callosum volume by Blokland, G.A.M., Maleki, N., Jovicich, J., Mesholam-Gately, R.I., DeLisi, L.E., Turner, J.A., Shenton, M.E., Voineskos, A.N., Kahn, R.S., Roffman, J.L., Holt, D.J., Ehrlich, S., Kikinis, Z., Dazzan, P., Murray, R.M., Lee, J., Sim, K., Lam, M., de Zwarte, S.M.C., Walton, E., Kelly, S., Picchioni, M.M., Bramon, E., Makris, N., David, A.S., Mondelli, V., Reinders, A.A.T.S., Oykhman, E., Morris, D.W., Gill, M., Corvin, A.P., Cahn, W., Ho, N., Liu, J., Gollub, R.L., Manoach, D.S., Calhoun, V.D., Sponheim, S.R., Buka, S.L., Cherkerzian, S., Thermenos, H.W., Dickie, E.W., Ciufolini, S., Reis Marques, T., Crossley, N.A., Purcell, S.M., Smoller, J.W., van Haren, N.E.M., Toulopoulou, T., Donohoe, G., Goldstein, J.M., Keshavan, M.S., Petryshen, T.L., del Re, E.C.

“…Background/Objective. Enlarged lateral ventricle (LV) volume and decreased volume in the corpus callosum (CC) are hallmarks of schizophrenia (SZ). We…”
Get full text

The SORL1 gene and convergent neural risk for Alzheimer’s disease across the human lifespan by Felsky, D, Szeszko, P, Yu, L, Honer, W G, De Jager, P L, Schneider, J A, Malhotra, A K, Lencz, T, Ikuta, T, Pipitone, J, Chakravarty, M M, Lobaugh, N J, Mulsant, B H, Pollock, B G, Kennedy, J L, Bennett, D A, Voineskos, A N

“…Prior to intervention trials in individuals genetically at-risk for late-onset Alzheimer’s disease, critical first steps are identifying where (neuroanatomic…”
Get full text

Association study of Cannabinoid receptor 1 ( ) gene in tardive dyskinesia by Tiwari, A K, Zai, C C, Likhodi, O, Voineskos, A N, Meltzer, H Y, Lieberman, J A, Potkin, S G, Remington, G, Müller, D J, Kennedy, J L

“…Tardive dyskinesia (TD) is a severe, debilitating movement disorder observed in 25–30% of the patients treated with typical antipsychotics. Cannabinoid…”
Get full text

The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia by Lett, T.A, Chakravarty, M.M, Felsky, D, Brandl, E.J, Tiwari, A.K, Goncalves, V.F, Rajji, T.K, Daskalakis, Z.J, Meltzer, H.Y, Lieberman, J.A, Lerch, J.P, Mulsant, B.H, Kennedy, J.L, Voineskos, A.N

Get full text

Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients by Zai, C C, Tiwari, A K, Basile, V, De Luca, V, Müller, D J, King, N, Voineskos, A N, Remington, G, Meltzer, H Y, Lieberman, J A, Potkin, S G, Kennedy, J L

“…Tardive dyskinesia (TD) is a side effect of chronic antipsychotic medication exposure. Abnormalities in dopaminergic activity in the nigro-striatal system have…”
Get full text